Cognitive differences in schizophrenia on long-term treatments with clozapine, risperidone and typical antipsychotics

International Clinical Psychopharmacology

Volumn 30, Issue 2, 2015, Pages 89-95

  Han, Mei ^a,b,c   Zhang, Xiang Yang ^c,d   Chen, Da Chun ^c   Tan, Yun Long ^c   Song, Chong Sheng ^c   Yu, Ying Hua ^a,b   Huang, Xu Feng ^a,b  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b SCHIZOPHRENIA RESEARCH INSTITUTE   (Australia)

^c PEKING UNIVERSITY   (China)

^d UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

antipsychotic drugs; cognitive deficits; schizophrenia; treatment

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; HALOPERIDOL; PERPHENAZINE; RISPERIDONE; SULPIRIDE; NEUROLEPTIC AGENT;

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT TOOL; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; CORRELATION ANALYSIS; DEPTH PERCEPTION; DRUG EFFECT; FEMALE; HUMAN; LANGUAGE ABILITY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEMORY; MIDDLE AGED; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; REPEATABLE BATTERY FOR THE ASSESSMENT OF NEUROPSYCHOLOGICAL STATUS; SCHIZOPHRENIA; SHORT TERM MEMORY; STATISTICAL ANALYSIS; SYMPTOMATOLOGY; CASE CONTROL STUDY; COGNITION DISORDERS; COMPLICATION; CROSS-SECTIONAL STUDY; DRUG EFFECTS; LANGUAGE; NEUROPSYCHOLOGICAL TEST; PSYCHOLOGY;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CLOZAPINE; COGNITION DISORDERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; LANGUAGE; MALE; MEMORY; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 84922412008     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000066     Document Type: Article

References (47)

1. Addy N, Levin ED (2002). Nicotine interactions with haloperidol, clozapine and risperidone and working memory function in rats. Neuropsychopharmacology 27:534-541.
2. Beninger RJ, Baker TW, Florczynski MM, Banasikowski TJ (2010). Regional differences in the action of antipsychotic drugs: implications for cognitive effects in schizophrenic patients. Neurotox Res 18:229-243.
3. Buchanan RW, Holstein C, Breier A (1994). The comparative efficacy and longterm effect of clozapine treatment on neuropsychological test performance. Biol Psychiatry 36:717-725.
4. Bymaster FP, Felder CC, Tzavara E, Nomikos GG, Calligaro DO, Mckinzie DL (2003). Muscarinic mechanisms of antipsychotic atypicality. Prog Neuropsychopharmacol Biol Psychiatry 27:1125-1143.
5. Daban C, Amado I, Bourdel MC, Loo H, Olié JP, Poirier MF, Krebs MO (2005). Cognitive dysfunctions in medicated and unmedicated patients with recentonset schizophrenia. J Psychiatr Res 39:391-398.
6. DeLeon A, Patel NC, Crismon ML (2004). Aripiprazole: a comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clin Ther 26:649-666.
7. Desmarais JE, Beauclair L, Margolese HC (2012). Anticholinergics in the era of atypical antipsychotics: short-term or long-term treatment? J Psychopharmacol 26:1167-1174.
8. Duff K, Humphreys Clark JD, O'Bryant SE, Mold JW, Schiffer RB, Sutker PB (2008). Utility of the RBANS in detecting cognitive impairment associated with Alzheimer's disease: sensitivity, specificity, and positive and negative predictive powers. Arch Clin Neuropsychol 23:603-612.
9. Flanagan RJ (2008). Side effects of clozapine and some other psychoactive drugs. Curr Drug Saf 3:115-122.
10. Gleissner U, Elger CE (2001). The hippocampal contribution to verbal fluency in patients with temporal lobe epilepsy. Cortex 37:55-63.
11. Goldberg TE, Greenberg RD, Griffin SJ, Gold JM, Kleinman JE, Pickar D, et al. (1993). The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. Br J Psychiatry 162:43-48.
12. Hill SK, Bishop JR, Palumbo D, Sweeney JA (2010). Effect of second-generation antipsychotics on cognition: current issues and future challenges. Expert Rev Neurother 10:43-57.
13. Hoff AL, Faustman WO, Wieneke M, Espinoza S, Costa M, Wolkowitz O, Csernansky JG (1996). The effects of clozapine on symptom reduction, neurocognitive function, and clinical management in treatment-refractory state hospital schizophrenic inpatients. Neuropsychopharmacology 15:361-369.
14. Houthoofd SA, Morrens M, Sabbe BG (2008). Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder. Clin Ther 30:1565-1589.
15. Kapur S, Seeman P (2001). Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 158:360-369.
16. Kay SR, Fiszbein A, Opler LA (1987). The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13:261-276.
17. Keefe RS, Harvey PD (2012). Cognitive impairment in schizophrenia. Handb Exp Pharmacol 213:11-37.
18. Keefe RS, Young CA, Rock SL, Purdon SE, Gold JM, Breier A. HGGN Study Group (2006). One-year double-blind study of the neurocognitive efficacy of olanzapine, risperidone, and haloperidol in schizophrenia. Schizophr Res 81:1-15.
19. Lewis SW, Barnes TR, Davies L, Murray RM, Dunn G, Hayhurst KP, et al. (2006). Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 32:715-723.
20. Lindenmayer JP, Iskander A, Park M, Apergi FS, Czobor P, Smith R, Allen D (1998). Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study. J Clin Psychiatry 59:521-527.
21. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, et al. CATIE Investigators (2006). Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 163:600-610.
22. Meltzer HY, McGurk SR (1999). The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233-255.
23. Minzenberg MJ, Poole JH, Benton C, Vinogradov S (2004). Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. Am J Psychiatry 161:116-124.
24. Mori K, Yamashita H, Nagao M, Horiguchi J, Yamawaki S (2002). Effects of anticholinergic drug withdrawal on memory, regional cerebral blood flow and extrapyramidal side effects in schizophrenic patients. Pharmacopsychiatry 35:6-11.
25. Nasrallah H (2003). A review of the effect of atypical antipsychotics on weight. Psychoneuroendocrinology 28 (Suppl 1):83-96.
26. Park T, Bae S, Choi S, Kang B, Kim K (2001). Inhibition of nicotinic acetylcholine receptors and calcium channels by clozapine in bovine adrenal chromaffin cells. Biochem Pharmacol 61:1011-1019.
27. Perlmuter LC, Nathan DM, Goldfinger SH, Russo PA, Yates J, Larkin M (1988). Triglyceride levels affect cognitive function in noninsulin-dependent diabetics. J Diabet Complications 2:210-213.
28. Perry EK, Perry RH (1995). Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn 28:240-258.
29. Pocivavsek A, Icenogle L, Levin ED (2006). Ventral hippocampal alpha7 and alpha4beta2 nicotinic receptor blockade and clozapine effects on memory in female rats. Psychopharmacology (Berl) 188:597-604.
30. Randolph C, Tierney MC, Mohr E, Chase TN (1998). The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS): preliminary clinical validity. J Clin Exp Neuropsychol 20:310-319.
31. Schooler NR (1994). Negative symptoms in schizophrenia: assessment of the effect of risperidone. J Clin Psychiatry 55 (Suppl):22-28.
32. Sharma T, Hughes C, Soni W, Kumari V (2003). Cognitive effects of olanzapine and clozapine treatment in chronic schizophrenia. Psychopharmacology (Berl) 169:398-403.
33. Sidlova M, Prasko J, Jelenova D, Kovacsova A, Latalova K, Sigmundova Z, Vrbova K (2011). The quality of life of patients suffering from schizophrenia-a comparison with healthy controls. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 155:173-180.
34. Simosky JK, Stevens KE, Adler LE, Freedman R (2003). Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism. Psychopharmacology (Berl) 165:386-396.
35. Stip E, Lussier I (1996). The effect of risperidone on cognition in patients with schizophrenia. Can J Psychiatry 41 (Suppl 2):S35-S40.
36. Suzuki H, Gen K, Inoue Y, Hibino H, Mikami A, Matsumoto H, Mikami K (2014). The influence of switching from risperidone to paliperidone on the extrapyramidal symptoms and cognitive function in elderly patients with schizophrenia: a preliminary open-label trial. Int J Psychiatry Clin Pract 18:58-62.
37. Takeuchi H, Suzuki T, Remington G, Bies RR, Abe T, Graff-Guerrero A, et al. (2013). Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: an open-label, randomized, controlled, pilot study. Schizophr Bull 39:993-998.
38. Terry AV Jr, Mahadik SP (2007). Time-dependent cognitive deficits associated with first and second generation antipsychotics: cholinergic dysregulation as a potential mechanism. J Pharmacol Exp Ther 320:961-968.
39. Thornton AE, Van Snellenberg JX, Sepehry AA, Honer W (2006). The impact of atypical antipsychotic medications on long-term memory dysfunction in schizophrenia spectrum disorder: a quantitative review. J Psychopharmacol 20:335-346.
40. Tomida K, Takahashi N, Saito S, Maeno N, Iwamoto K, Yoshida K, et al. (2010). Relationship of psychopathological symptoms and cognitive function to subjective quality of life in patients with chronic schizophrenia. Psychiatry Clin Neurosci 64:62-69.
41. Umegaki H, Kawamura T, Umemura T, Kawano N (2014). Factors associated with cognitive decline in older adults with type 2 diabetes mellitus during a 6-year observation. Geriatr Gerontol Int. doi: 10.1111/ggi.12273 [Epub ahead of print].
42. Velligan DI, Bow-Thomas CC, Mahurin RK, Miller AL, Halgunseth LC (2000). Do specific neurocognitive deficits predict specific domains of community function in schizophrenia? J Nerv Ment Dis 188:518-524.
43. Vyas NS, Patel NH, Puri BK (2011). Neurobiology and phenotypic expression in early onset schizophrenia. Early Interv Psychiatry 5:3-14.
44. Westerink BH (2002). Can antipsychotic drugs be classified by their effects on a particular group of dopamine neurons in the brain? Eur J Pharmacol 455:1-18.
45. Woods SW (2003). Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64:663-667.
46. Woodward ND, Purdon SE, Meltzer HY, Zald DH (2005). A meta-analysis of neuropsychological change to clozapine, olanzapine, quetiapine, and risperidone in schizophrenia. Int J Neuropsychopharmacol 8:457-472.
47. Zhang BH, Tan YL, Zhang WF, Wang ZR, Yang GG, Shi C, et al. (2009). Repeatable Battery for the Assessment of Neuropsychological Status (RBANS) as a Screening Test in Chinese: reliability and validity. Chin Mental Health J 28:865-869.